Kardigan, Inc.(KARD)

Biotechnology · Princeton, NJ

$14.02-1.22 (-8.04%)

Delayed quote: Oct 6, 2026, 2:19 PM EDT

EV/EBITDA Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBITDA ratio is N/A as of 2026-10-06T18:21:53.373Z.

Stored calculation inputs

Calculation as of: 2026-10-06T18:21:53.373Z.

Quote observation: 2026-10-06T18:19:56.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 1,252,087,781
Total debt · period ending 2026-06-30: 13,347,000
Cash · period ending 2026-06-30: 384,005,000
TTM operating EBITDA · period ending 2026-06-30: N/A

FMP input reference: 6dd2a4984e4340952b62e9ecd156f35eed99e3c78779d37ae6f95d3f5c845125

EV/Sales|P/E Ratio|EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

KARD EV/EBITDA Ratio Metrics

EV/EBITDA RATIO

N/A

KARD Competitors' EV/EBITDA Ratio

KARD

Kardigan, Inc.

Current

Market Cap

$1.25B

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

OMDA

Omada Health

vs KARD

Market Cap

$1.23B

EV/EBITDA Ratio

144.62x

TTM Avg

171.92x

3Y Avg

171.92x

5Y Avg

171.92x

INNV

Innovage Holding Corp.

vs KARD

Market Cap

$1.22B

EV/EBITDA Ratio

14.35x

TTM Avg

31.81x

3Y Avg

87.57x

5Y Avg

54.63x

CRON

Cronos Group Inc.

vs KARD

Market Cap

$1.22B

EV/EBITDA Ratio

27.95x

TTM Avg

20.27x

3Y Avg

20.27x

5Y Avg

20.27x

MNKD

MannKind Corporation

vs KARD

Market Cap

$1.21B

EV/EBITDA Ratio

52.08x

TTM Avg

34.34x

3Y Avg

36.39x

5Y Avg

36.39x

ORIC

ORIC Pharmaceuticals, Inc.

vs KARD

Market Cap

$1.20B

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

TYRA

Tyra Biosciences, Inc.

vs KARD

Market Cap

$1.19B

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

DRTS

Alpha Tau Medical Ltd

vs KARD

Market Cap

$1.32B

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

DMRA

Damora Therapeutics, Inc.

vs KARD

Market Cap

$1.17B

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

COAG

Hemab Therapeutics Holdings, Inc. Common Stock

vs KARD

Market Cap

$1.33B

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/EBITDA RATIO	TTM	3Y	5Y
Kardigan, Inc. (KARD)	$1.25B	N/A	N/A	N/A	N/A
Omada Health (OMDA)vs ›	$1.23B	144.62x	171.92x	171.92x	171.92x
Innovage Holding Corp. (INNV)vs ›	$1.22B	14.35x	31.81x	87.57x	54.63x
Cronos Group Inc. (CRON)vs ›	$1.22B	27.95x	20.27x	20.27x	20.27x
MannKind Corporation (MNKD)vs ›	$1.21B	52.08x	34.34x	36.39x	36.39x
ORIC Pharmaceuticals, Inc. (ORIC)vs ›	$1.20B	N/A	N/A	N/A	N/A
Tyra Biosciences, Inc. (TYRA)vs ›	$1.19B	N/A	N/A	N/A	N/A
Alpha Tau Medical Ltd (DRTS)vs ›	$1.32B	N/A	N/A	N/A	N/A
Damora Therapeutics, Inc. (DMRA)vs ›	$1.17B	N/A	N/A	N/A	N/A
Hemab Therapeutics Holdings, Inc. Common Stock (COAG)vs ›	$1.33B	N/A	N/A	N/A	N/A

EV/EBITDA Ratio Formula & Definition

EV/EBITDA = Enterprise Value / EBITDA (TTM)

Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/Sales P/E Ratio EBITDA All Metrics